MedNess

🗞 Join Avraneel on MedNess this week as he discusses FDA’s approval of Astellas Pharma’s Vyloy,the first and only claudin-18.2-targeted antibody to treat gastric cancer. 👉 Subscribe to get our weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ♻ Share and repost to get the conversation going. 🤝MedNess Team Avraneel Paul, PhD, Author Jyothi Inampudi PhD & Anusha Jayaraman, PhD Managing Editors Himanshi Agarwal, PhD & Ananya Rakshit, Ph.D. Social Media Managers

This week on MedNess, Vinoth discusses the FDA’s recent approval of zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), for treatment of adults with locally advanced, unresectable, or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Used with chemotherapy, Vyloy targets HER2-negative tumors that express the unique biomarker claudin 18.2 (CLDN18.2), offering a novel approach to treatment in patients. Stay tuned to Avraneel’s story to explore more about the potential of Vyloy and its role in the evolving market, as well as an inside look at emerging competitors in the field. 📰 Subscribe to get the weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Disease Disruptors Team Dr. Vinoth Khandelwal, Author Jyothi Inampudi PhD & Anusha Jayaraman, PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers

This week on MedNess, Rueben discusses the FDA’s recent approval of AbbVie’s subcutaneous 24-hour continuous infusion drug,VYALEV to reduce motor fluctuations in advanced stage Parkinson’s Disease patients. 📰 Subscribe to get the weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Medness Neuro Team Rueben Das, PhD Anusha Jayaraman, PhD & Jyothi Inampudi PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers

This week on MedNess, Vinoth discusses the FDA’s recent approval of an exciting new combination therapy that includes inavolisib (Itovebi), palbociclib, and fulvestrant for treating endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. 📰 Subscribe to get the weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Disease Disruptors Team Dr. Vinoth Khandelwal, Author Anusha Jayaraman, PhD & Jyothi Inampudi PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers

This week on MedNess, join Vinny as she brings another interesting summary from a European observational study. This study discusses how glucose (2-hPG) is a better marker than HbA1c in predicting cardiovascular events for coronary artery disease patients.   📰Subscribe to get our weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD   ✍️ Metabolic Disorders Team Vinny Negi, PhD, Author Anusha Jayaraman, PhD, & Jyothi Inampudi PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Manage

This week on MedNess Care for Rare, Malini discusses Q fever, an infectious disease caused by the bacterium Coxiella burnetii. While it primarily affects livestock, humans can also become infected by inhaling contaminated aerosols or consuming unpasteurized dairy products. Most acute cases resolve on their own, but antibiotic treatments such as doxycycline can significantly alleviate symptoms and reduce complications. In contrast, chronic Q fever requires a more intensive treatment strategy and careful monitoring. Early diagnosis and effective management are essential for better outcomes, highlighting the need for increased awareness and education about this disease. Malini covers both the fundamentals of Q fever and its treatment options. 📰 Subscribe to get our weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Care For Rare Team Malini Gupta, Ph.D., Author Anusha Jayaraman, PhD & Jyothi Inampudi PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers

🗞 This week on MedNess "Care for Rare," Malini delves into the world of progeria (HGPS), a rare genetic disorder that leads to rapid aging in children. In her exploration of treatment options, she will discuss the groundbreaking advancements in gene therapy and CRISPR technology, both of which hold promise for directly addressing the genetic mutations responsible for the condition. Malini will share insights into how these innovative therapies aim to repair or replace the defective gene, potentially transforming the lives of affected children. She’ll also highlight the latest FDA-approved therapy that has emerged in the fight against progeria. 📰 Subscribe to get our weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Care For Rare Team Malini Gupta, Ph.D., Author Anusha Jayaraman, PhD & Jyothi Inampudi PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers

📢 Breakthrough alert! 🎉 🗞 This week in MedNess Metabolic Diseases column, join Vinny as she discusses a breakthrough study on treatment of type 1 diabetes. Type 1 diabetes affected individuals can not produce insulin, a hormone required to make sugar (glucose) enter into our cells so that they can utilize it to produce energy. Scientists solved it by transplanting stem cells (iPSCs) which can produce insulin and Hurray! It worked! ♻ Repost and share it with your connections. 🖐Do not forget to subscribe to get the weekly free newsletter on MedNess Disease Disruptors, Care for rare and Metabolic diseases directly in your inbox at https://lnkd.in/gBN7dVs ✍MedNess Care for Rare Team Vinny Negi, PhD, PhD, Author Jyothi Inampudi PhD, & Anusha Jayaraman, PhD, Managing Editors Himanshi Agarwal, PhD & Ananya Rakshit, Ph.D., Social Media Managers

🗞 This week on MedNess, Vinoth covers the FDA’s approval of nivolumab, combined with platinum-doublet chemotherapy, as a neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC). 📰 Subscribe to get the weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Disease Disruptors Team Dr. Vinoth Khandelwal, Author Jyothi Inampudi PhD & Anusha Jayaraman, PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Manager

🗞 This week on MedNess “Care for Rare”, Malini will focus on Progeria or Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder that causes rapid aging in children. She will discuss its underlying genetic causes, the small population it affects, and the limited resources available for support and research. In Part I, Malini will explain the fundamentals of this condition, including its causes and the significant challenges it presents. Don’t miss Part II next week, where she will delve into current treatment options and emerging therapies aimed at improving the quality of life for those affected. 📰 Subscribe to get our weekly free newsletter directly in your inbox at https://lnkd.in/gBN7dVsD ✍️ Care For Rare Team Malini Gupta, Ph.D., Author Jyothi Inampudi PhD & Anusha Jayaraman, PhD, Managing Editors Ananya Rakshit, Ph.D., & Himanshi Agarwal, PhD, Social Media Managers